CERE - Cerevel Therapeutics to Present at Upcoming Investor Conferences | Benzinga
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the management team will participate in two upcoming investor conferences during the month of November. President and chief executive officer Ron Renaud will also participate in fireside chats at both conferences.
| Event: |
| Jefferies London Healthcare Conference |
| Date: |
| November 14, 2023 |
| Time: |
| 9:00 a.m. GMT fireside chat |
| Event: |
| 6th Annual Evercore ISI HealthCONx Conference |
| Date: |
| November 30, 2023 |
| Time: |
| 9:10 a.m. ET fireside chat |
Live webcasts of the fireside chats will be available on the investors section of Cerevel's website at investors.cerevel.com. Following the live webcast, an archived version of the call will be available on the website.
About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise in neurocircuitry with a focus on targeted receptor subtype selectivity and a differentiated approach to pharmacology. Cerevel Therapeutics has a diversified pipeline comprised of five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson's disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through ...